ARIAD Announces Ponatinib Presentations at Annual American Society of Hematology Meeting

  ARIAD Announces Ponatinib Presentations at Annual American Society of
  Hematology Meeting

Business Wire

CAMBRIDGE, Mass. -- December 03, 2012

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentations
on ponatinib, its investigational BCR-ABL inhibitor, that will take place at
the 54th Annual Meeting of the American Society of Hematology (ASH) being held
in Atlanta, December 8 to 11, 2012. Updated and new results on the PACE trial
will be featured in five presentations – two oral and three posters.

PACE Trial: 12-Month Follow Up in Chronic Phase Patients

                  A Pivotal Phase 2 Trial of Ponatinib in Patients with
                  Chronic Myeloid Leukemia (CML) and Philadelphia
Title:           Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)
                  Resistant or Intolerant to Dasatinib or Nilotinib, or with
                  the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE
                  Trial
Oral Session:     632. Chronic Myeloid Leukemia - Therapy I Session
Date & Time:      Sunday, December 9, 2012, 4:30 p.m.
Abstract No.:     163
Presenter:        Jorge E. Cortes, M.D. (The University of Texas MD Anderson
                  Cancer Center)
Location:         Georgia World Congress Center, A411-A412

PACE Trial: Efficacy and Safety in Advanced Phase Patients

                  Efficacy and Safety of Ponatinib in Patients with
                  Accelerated Phase or Blast Phase Chronic Myeloid Leukemia
Title:            (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute
                  Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the
                  PACE Trial
Oral Session:     632. Chronic Myeloid Leukemia - Therapy II Session
Date and Time:    Tuesday, December 11, 2012 at 8:00 a.m.
Abstract No.:     915
Presenter:        Hagop M. Kantarjian, M.D. (The University of Texas MD
                  Anderson Cancer Center)
Location:         Georgia World Congress Center, A411-A412

PACE Trial: Results According to Prior Tyrosine Kinase Inhibitor Therapy

                  Efficacy and Safety of Ponatinib According to Prior Approved
Title:            Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with
                  Chronic Myeloid Leukemia in Chronic Phase (CP‐CML): Results
                  from the PACE Trial
Poster Session:   632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time:      Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.:     3749
Presenter:        Dong-Wook Kim, M.D., Ph.D. (Mary’s Hospital, The Catholic
                  University of Korea)
Location:         Georgia World Congress Center, Hall B1-B2

PACE Trial: Molecular Response Data

                  Molecular Responses with Ponatinib in Patients with
Title:            Philadelphia Chromosome Positive (Ph+) Leukemia: Results
                  From the PACE Trial
Poster Session:   632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time:      Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.:     3763
Author:           Andreas Hochhaus, M.D., University Medical Center Jena in
                  Germany
Location:         Georgia World Congress Center, Hall B1-B2

PACE Trial: Multivariate Analysis of Parameters

                  Multivariate Analyses of the Clinical and Molecular
                  Parameters Associated with Efficacy and Safety in Patients
Title:            with Chronic Myeloid Leukemia (CML) and Philadelphia
                  Chromosome‐Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
                  Treated with Ponatinib in the PACE Trial
Poster Session:   632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time:      Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.:     3747
Presenter:        Michael Mauro, M.D. (Oregon Health & Science University)
Location:         Georgia World Congress Center, Hall B1-B2

Phase 1 Trial: Long-term Results

                  Long-Term Anti-Leukemic Activity of Ponatinib in Patients
Title:            with Philadelphia Chromosome-Positive Leukemia: Updated
                  Results from an Ongoing Phase 1 Study
Poster Session:   632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time:      Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.:     3743
Presenter:        Michael Deininger, M.D., Ph.D. (University of Utah School of
                  Medicine Huntsman Cancer Institute)
Location:         Georgia World Congress Center, Hall B1-B2
                  

About ARIAD

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on
the discovery, development and commercialization of medicines to transform the
lives of cancer patients. ARIAD’s approach to structure-based drug design has
led to several internally discovered, molecularly targeted medicines for
drug-resistant or difficult-to-treat cancers, including chronic myeloid
leukemia and non-small cell lung cancer. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

Contact:

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com